# Andrew H. Wei

Source: https://onco.cc/people/andrew-wei/  
OnCo record `andrew-wei` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML.

## Summary

Andrew Wei was principal investigator of VIALE-C (venetoclax plus low-dose cytarabine) and first author of QUAZAR AML-001, which showed oral azacitidine maintenance improves survival after remission in older AML patients, the first maintenance therapy approved in AML. He leads the Australasian Leukaemia and Lymphoma Group AML programme and the venetoclax-based intensive chemotherapy trials.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: aml; venetoclax; australia
- Role: Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne
- Specialisms: Acute myeloid leukaemia; Venetoclax; Measurable residual disease; Maintenance therapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Wei%20AH%5BAuthor%5D%20venetoclax%20azacitidine

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/), [Walter and Eliza Hall Institute of Medical Research](https://onco.cc/institutions/wehi/)
- journals: [Blood](https://onco.cc/journals/blood/)

---
JSON: https://onco.cc/api/v1/entities/andrew-wei.json